SAB Biotherapeutics Advances SAB-142 into Phase 2b Clinical Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SABS?
Source: Newsfilter
- Clinical Study Progress: SAB Biotherapeutics has dosed multiple patients in the registrational Phase 2b SAFEGUARD study of SAB-142, with enrollment expected to complete by the end of 2026 and topline data anticipated in the second half of 2027, indicating significant advancements in treating type 1 diabetes.
- Successful Financing: The company raised $175 million in an oversubscribed private placement, fully funding the SAFEGUARD study, which not only strengthens its financial position but also secures the necessary resources for ongoing clinical development.
- Positive Clinical Data: Phase 1 trials of SAB-142 in healthy volunteers and T1D cohorts demonstrated a favorable safety profile and low immunogenicity, supporting its potential for chronic outpatient administration, thereby opening new avenues for type 1 diabetes treatment.
- Executive Appointments: David Zaccardelli and Rita Jain have been appointed as Chair and Independent Director of the Board, respectively, both bringing over 20 years of experience in biopharmaceuticals, which is expected to enhance the company's strategic direction and clinical research efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SABS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SABS
Wall Street analysts forecast SABS stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.790
Low
7.00
Averages
10.33
High
15.00
Current: 3.790
Low
7.00
Averages
10.33
High
15.00
About SABS
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SAB Biotherapeutics Reports 2025 Financial Highlights
- Net Income Improvement: SAB Biotherapeutics reported a net income of $13.3 million for 2025, a significant turnaround from a net loss of $34.1 million in 2024, indicating a strong recovery in financial performance that boosts investor confidence.
- Strong Cash Position: As of December 31, 2025, the company held $143.5 million in cash, cash equivalents, and available-for-sale securities, providing a solid operational runway through 2028, which enhances its long-term growth potential.
- Increased R&D Spending: Research and development expenses rose to $34.4 million in 2025 from $30.3 million in 2024, reflecting the company's ongoing commitment to innovation and product development, which is crucial for maintaining competitive advantage in the market.
- Significant Other Income Growth: Other income surged to $62.2 million in 2025, up from $8.8 million in 2024, primarily driven by changes in the fair value of warrant liabilities, showcasing effective financial management and strategic asset utilization.
See More
SAB Biotherapeutics Advances SAB-142 into Phase 2b Clinical Study
- Clinical Study Progress: SAB Biotherapeutics has dosed multiple patients in the registrational Phase 2b SAFEGUARD study of SAB-142, with enrollment expected to complete by the end of 2026 and topline data anticipated in the second half of 2027, indicating significant advancements in treating type 1 diabetes.
- Successful Financing: The company raised $175 million in an oversubscribed private placement, fully funding the SAFEGUARD study, which not only strengthens its financial position but also secures the necessary resources for ongoing clinical development.
- Positive Clinical Data: Phase 1 trials of SAB-142 in healthy volunteers and T1D cohorts demonstrated a favorable safety profile and low immunogenicity, supporting its potential for chronic outpatient administration, thereby opening new avenues for type 1 diabetes treatment.
- Executive Appointments: David Zaccardelli and Rita Jain have been appointed as Chair and Independent Director of the Board, respectively, both bringing over 20 years of experience in biopharmaceuticals, which is expected to enhance the company's strategic direction and clinical research efforts.
See More
SAB Biotherapeutics Promotes SAB-142 for Type 1 Diabetes at Oppenheimer Conference
- Trial Design: SAB-142 is being evaluated in the global Phase IIb SAFEGUARD trial targeting newly diagnosed Stage 3 T1D patients with dosing every six months across three arms (2.5 mg/kg, 1.5 mg/kg, and placebo), with a primary endpoint of C-peptide at one year, aiming for last patient in by end-2026 and top-line data in H2 2027.
- Market Potential: SAB identifies an initial addressable market of approximately 64,000 new Stage 3 diagnoses annually in the U.S., and with Tzield priced at $200,000, SAB-142 presents a significant market opportunity, especially as redosing could expand commercial prospects to meet urgent patient needs.
- Financial Position: Ending 2025 with $140 million in cash, SAB is well-positioned to fund the SAFEGUARD trial through top-line readout and into 2028, ensuring adequate financial resources during critical development phases.
- Technical Advantages: As a fully human anti-thymocyte globulin, SAB-142 avoids the serum sickness and anti-drug antibody issues associated with rabbit ATG, offering better tolerability and redosing capabilities, aimed at inducing T-cell exhaustion to protect pancreatic beta cells and enhance insulin production in patients.
See More
SAB Biotherapeutics Advances SAB-142 Clinical Trial for Stage 3 Diabetes Treatment Following Positive Phase 1 Results
- Safety Confirmation: The Phase 1 trial involving 62 healthy volunteers and 6 T1D patients demonstrated that SAB-142 did not cause serum sickness or any drug-related serious adverse events, indicating a strong safety profile that could position it as a new treatment option for diabetes.
- Dosing Flexibility: SAB-142 showed good tolerability across various doses (0.03-4.5mg/kg), and lymphopenia observed after dosing corrected rapidly within 1-3 days, highlighting its potential for safe redosing in patients.
- Clinical Advancement: Following positive Phase 1 results, SAB Biotherapeutics has initiated the Phase 2b SAFEGUARD trial, set to recruit patients at multiple global sites, with plans to dose the first patient by year-end, further assessing its efficacy in new-onset stage 3 diabetes patients.
- Market Potential: As a potentially disease-modifying immunotherapy, SAB-142 aims to delay the progression of T1D, addressing the urgent need for novel diabetes treatment options and potentially transforming the treatment landscape in this field.
See More
SAB Biotherapeutics Confirms SAB-142 Safety, Advances to Phase 2b Clinical Trial
- Safety Confirmation: The Phase 1 trial of SAB-142 involving 62 healthy volunteers and 6 T1D patients demonstrated no serum sickness or immunogenicity, with no drug-related serious adverse events reported, indicating a safety profile superior to traditional treatments.
- Clinical Advancement: Following positive Phase 1 results, SAB-142 has advanced to the registrational Phase 2b SAFEGUARD trial aimed at evaluating its efficacy in new-onset stage 3 T1D patients, with dosing expected to commence by year-end.
- Dosing Flexibility: The drug exhibited good tolerability after multiple doses without sustained lymphopenia, showcasing its potential for safe redosing, which could transform the treatment paradigm for T1D.
- Global Recruitment: The SAFEGUARD trial is actively recruiting patients at multiple sites worldwide, as SAB Biotherapeutics aims to provide new treatment options for T1D patients, addressing the urgent market demand for effective therapies.
See More
SAB BIO Announces Financial Results for Third Quarter and Key Business Updates
Initiation of SAFEGUARD Trial: SAB Biotherapeutics has launched the registrational Phase 2b SAFEGUARD trial for SAB-142, targeting new-onset Stage 3 autoimmune type 1 diabetes (T1D) patients, with plans to dose the first patient by year-end.
Clinical Data Presentation: Recent presentations at EASD and ISPAD highlighted the favorable safety profile and multi-specific mechanism of action of SAB-142, reinforcing its potential as a disease-modifying treatment for T1D.
Financial Position: As of September 30, 2025, SAB Biotherapeutics reported a strong cash position of $161.5 million, enabling continued investment in the SAB-142 program and other research activities.
Upcoming Milestones: The company is on track to share additional data from the SAFEGUARD trial in the second half of 2027 and finalize Phase 1 study results by the end of this year.
See More
SAB Biotherapeutics Reports 2025 Financial Highlights
- Net Income Improvement: SAB Biotherapeutics reported a net income of $13.3 million for 2025, a significant turnaround from a net loss of $34.1 million in 2024, indicating a strong recovery in financial performance that boosts investor confidence.
- Strong Cash Position: As of December 31, 2025, the company held $143.5 million in cash, cash equivalents, and available-for-sale securities, providing a solid operational runway through 2028, which enhances its long-term growth potential.
- Increased R&D Spending: Research and development expenses rose to $34.4 million in 2025 from $30.3 million in 2024, reflecting the company's ongoing commitment to innovation and product development, which is crucial for maintaining competitive advantage in the market.
- Significant Other Income Growth: Other income surged to $62.2 million in 2025, up from $8.8 million in 2024, primarily driven by changes in the fair value of warrant liabilities, showcasing effective financial management and strategic asset utilization.
See More
SAB Biotherapeutics Advances SAB-142 into Phase 2b Clinical Study
- Clinical Study Progress: SAB Biotherapeutics has dosed multiple patients in the registrational Phase 2b SAFEGUARD study of SAB-142, with enrollment expected to complete by the end of 2026 and topline data anticipated in the second half of 2027, indicating significant advancements in treating type 1 diabetes.
- Successful Financing: The company raised $175 million in an oversubscribed private placement, fully funding the SAFEGUARD study, which not only strengthens its financial position but also secures the necessary resources for ongoing clinical development.
- Positive Clinical Data: Phase 1 trials of SAB-142 in healthy volunteers and T1D cohorts demonstrated a favorable safety profile and low immunogenicity, supporting its potential for chronic outpatient administration, thereby opening new avenues for type 1 diabetes treatment.
- Executive Appointments: David Zaccardelli and Rita Jain have been appointed as Chair and Independent Director of the Board, respectively, both bringing over 20 years of experience in biopharmaceuticals, which is expected to enhance the company's strategic direction and clinical research efforts.
See More
SAB Biotherapeutics Promotes SAB-142 for Type 1 Diabetes at Oppenheimer Conference
- Trial Design: SAB-142 is being evaluated in the global Phase IIb SAFEGUARD trial targeting newly diagnosed Stage 3 T1D patients with dosing every six months across three arms (2.5 mg/kg, 1.5 mg/kg, and placebo), with a primary endpoint of C-peptide at one year, aiming for last patient in by end-2026 and top-line data in H2 2027.
- Market Potential: SAB identifies an initial addressable market of approximately 64,000 new Stage 3 diagnoses annually in the U.S., and with Tzield priced at $200,000, SAB-142 presents a significant market opportunity, especially as redosing could expand commercial prospects to meet urgent patient needs.
- Financial Position: Ending 2025 with $140 million in cash, SAB is well-positioned to fund the SAFEGUARD trial through top-line readout and into 2028, ensuring adequate financial resources during critical development phases.
- Technical Advantages: As a fully human anti-thymocyte globulin, SAB-142 avoids the serum sickness and anti-drug antibody issues associated with rabbit ATG, offering better tolerability and redosing capabilities, aimed at inducing T-cell exhaustion to protect pancreatic beta cells and enhance insulin production in patients.
See More
SAB Biotherapeutics Advances SAB-142 Clinical Trial for Stage 3 Diabetes Treatment Following Positive Phase 1 Results
- Safety Confirmation: The Phase 1 trial involving 62 healthy volunteers and 6 T1D patients demonstrated that SAB-142 did not cause serum sickness or any drug-related serious adverse events, indicating a strong safety profile that could position it as a new treatment option for diabetes.
- Dosing Flexibility: SAB-142 showed good tolerability across various doses (0.03-4.5mg/kg), and lymphopenia observed after dosing corrected rapidly within 1-3 days, highlighting its potential for safe redosing in patients.
- Clinical Advancement: Following positive Phase 1 results, SAB Biotherapeutics has initiated the Phase 2b SAFEGUARD trial, set to recruit patients at multiple global sites, with plans to dose the first patient by year-end, further assessing its efficacy in new-onset stage 3 diabetes patients.
- Market Potential: As a potentially disease-modifying immunotherapy, SAB-142 aims to delay the progression of T1D, addressing the urgent need for novel diabetes treatment options and potentially transforming the treatment landscape in this field.
See More
SAB Biotherapeutics Confirms SAB-142 Safety, Advances to Phase 2b Clinical Trial
- Safety Confirmation: The Phase 1 trial of SAB-142 involving 62 healthy volunteers and 6 T1D patients demonstrated no serum sickness or immunogenicity, with no drug-related serious adverse events reported, indicating a safety profile superior to traditional treatments.
- Clinical Advancement: Following positive Phase 1 results, SAB-142 has advanced to the registrational Phase 2b SAFEGUARD trial aimed at evaluating its efficacy in new-onset stage 3 T1D patients, with dosing expected to commence by year-end.
- Dosing Flexibility: The drug exhibited good tolerability after multiple doses without sustained lymphopenia, showcasing its potential for safe redosing, which could transform the treatment paradigm for T1D.
- Global Recruitment: The SAFEGUARD trial is actively recruiting patients at multiple sites worldwide, as SAB Biotherapeutics aims to provide new treatment options for T1D patients, addressing the urgent market demand for effective therapies.
See More
SAB BIO Announces Financial Results for Third Quarter and Key Business Updates
Initiation of SAFEGUARD Trial: SAB Biotherapeutics has launched the registrational Phase 2b SAFEGUARD trial for SAB-142, targeting new-onset Stage 3 autoimmune type 1 diabetes (T1D) patients, with plans to dose the first patient by year-end.
Clinical Data Presentation: Recent presentations at EASD and ISPAD highlighted the favorable safety profile and multi-specific mechanism of action of SAB-142, reinforcing its potential as a disease-modifying treatment for T1D.
Financial Position: As of September 30, 2025, SAB Biotherapeutics reported a strong cash position of $161.5 million, enabling continued investment in the SAB-142 program and other research activities.
Upcoming Milestones: The company is on track to share additional data from the SAFEGUARD trial in the second half of 2027 and finalize Phase 1 study results by the end of this year.
See More
